The Trump administration advanced federal marijuana policy through an April 2026 executive order directing expedited review under the Controlled Substances Act. Acting Attorney General Todd Blanche issued a final order effective April 28 that moved FDA-approved cannabis products and state-licensed medical marijuana into Schedule III while launching a new administrative hearing on broader rescheduling of all marijuana from Schedule I. That hearing ran from June 29 to no later than July 15, 2026, with participants limited largely to rescheduling opponents; the DEA later filed briefs supporting a recommendation for Schedule III based on accepted medical use. A federal appeals court rejected challenges seeking to halt the process in early September. The administrative law judge’s recommendation remains pending, with any final rule subject to further review and potential litigation.
Riepilogo sperimentale generato dall'AI con riferimento ai dati di Polymarket. Questo non è un consiglio di trading e non ha alcun ruolo nella risoluzione di questo mercato. · Aggiornato$810,020 Vol.
30 set 2026
30 settembre
1%
31 dicembre
15%
$810,020 Vol.
30 settembre
$679 Vol.
1%
31 dicembre
$199,771 Vol.
15%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.The Trump administration advanced federal marijuana policy through an April 2026 executive order directing expedited review under the Controlled Substances Act. Acting Attorney General Todd Blanche issued a final order effective April 28 that moved FDA-approved cannabis products and state-licensed medical marijuana into Schedule III while launching a new administrative hearing on broader rescheduling of all marijuana from Schedule I. That hearing ran from June 29 to no later than July 15, 2026, with participants limited largely to rescheduling opponents; the DEA later filed briefs supporting a recommendation for Schedule III based on accepted medical use. A federal appeals court rejected challenges seeking to halt the process in early September. The administrative law judge’s recommendation remains pending, with any final rule subject to further review and potential litigation.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Mercato aperto: Jul 31, 2026, 5:46 PM ET
Volume
$810,020Data di fine
1 gen 2027Mercato aperto
Jul 31, 2026, 5:46 PM ETRisolutore
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.The Trump administration advanced federal marijuana policy through an April 2026 executive order directing expedited review under the Controlled Substances Act. Acting Attorney General Todd Blanche issued a final order effective April 28 that moved FDA-approved cannabis products and state-licensed medical marijuana into Schedule III while launching a new administrative hearing on broader rescheduling of all marijuana from Schedule I. That hearing ran from June 29 to no later than July 15, 2026, with participants limited largely to rescheduling opponents; the DEA later filed briefs supporting a recommendation for Schedule III based on accepted medical use. A federal appeals court rejected challenges seeking to halt the process in early September. The administrative law judge’s recommendation remains pending, with any final rule subject to further review and potential litigation.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Volume
$810,020Data di fine
1 gen 2027Mercato aperto
Jul 31, 2026, 5:46 PM ETRisolutore
0x65070BE91...The Trump administration advanced federal marijuana policy through an April 2026 executive order directing expedited review under the Controlled Substances Act. Acting Attorney General Todd Blanche issued a final order effective April 28 that moved FDA-approved cannabis products and state-licensed medical marijuana into Schedule III while launching a new administrative hearing on broader rescheduling of all marijuana from Schedule I. That hearing ran from June 29 to no later than July 15, 2026, with participants limited largely to rescheduling opponents; the DEA later filed briefs supporting a recommendation for Schedule III based on accepted medical use. A federal appeals court rejected challenges seeking to halt the process in early September. The administrative law judge’s recommendation remains pending, with any final rule subject to further review and potential litigation.
Riepilogo sperimentale generato dall'AI con riferimento ai dati di Polymarket. Questo non è un consiglio di trading e non ha alcun ruolo nella risoluzione di questo mercato. · Aggiornato
Fai attenzione ai link esterni.
Fai attenzione ai link esterni.
Domande frequenti